Subscribe To
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) 90 patients completed enrollment across 11 countries worldwide Interim safety and efficacy data from the Phase 3 “DRAGON” trial for STGD1 is expected […] The post Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant...
Read More
Content Topics
Belite
Completes
Enrollment
Pivotal
Global
Phase
Dragon
Evaluating
Tinlarebant
Stargardt
Disease
Forex
Posted: Jul 24 2023, 10:04
Author Name: forextv
Views: 080847